SHALBY145.25

Shalby Limited

· Pharma & Health
₹ CrorePeersGKSLGPTHEALTHINDRAMEDCOARTEMISMEDLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹1,562 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt314.0426.7539.6539.6
Net Debt206.1297.3455.5455.5
Total Debt/Equity0.310.430.540.54
Net Debt/Equity0.200.300.450.45
Total Debt/EBITDA1.773.223.783.78
Net Debt/EBITDA1.162.243.193.19
Interest Coverage (EBIT/Interest)7.781.731.871.87
Total Debt/Total Capital %23.7530.0134.9234.92
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.